All 32 US banks cleared the Fed's 2026 stress test. JPMorgan launched a $50B buyback. Morgan Stanley raised its dividend 15%. The headline says capital strength. The signal is regulatory regime change — stress capital buffers are now locked through 2027 and the industry just got its longest planning
The Hang Seng's 5.24% weekly drop and the HSCEI's slide to 22% off its January peak look like a China bear market on the surface. They aren't. The selling originated in leveraged Korean AI books and propagated through Asian time zones into the most liquid AI proxies in Hong Kong. The China story is
OpenAI's tilt toward a 2027 IPO didn't just delay a deal — it inverted every position pre-built around a defining 2026 catalyst. SoftBank fell 13%, the underwriting banks shed 4%, and the AI capex re-rating just lost its anchor. The trade hasn't died. It's been re-routed.
May PCE breached 4% for the first time in three years. The Fed's own dot plot expects hikes. Yet the 2-year Treasury yield fell on the print, July hike odds collapsed, and the rates market said the opposite of what the data said. The trade is in the divergence.
Merck KGaA's $11.3 billion cash bid for Bio-Techne is not another pharma M&A headline. At 10x sales for a research tools platform, it is a strategic admission that the sub-sector cycle has bottomed and the multiples have over-corrected. The implications run well past one deal.
Brent has collapsed from $126 to $75 in six weeks. Macquarie, JP Morgan, Goldman and S&P Global have all cut forecasts in the past 72 hours. The trade is no longer about Hormuz. It is about which forecaster capitulates last.
Mark Walter just closed on the Lakers at a $10 billion valuation, the highest ever paid for a North American sports franchise. Sportico marks the Knicks plus the Rangers at $13.5 billion. MSG Sports trades at $9.6 billion. The 29% gap is now a research thesis, not a footnote.
Nvidia just raised $25 billion with $85 billion of orders. Morgan Stanley sees $570 billion of AI-related debt by year-end. The trade is not in the equities the bonds finance — it is in the spreads the bonds are setting.
Japan deployed $73 billion in foreign reserves, the BOJ hiked to a 31-year high, and the yen still printed 161.80. The signal is not weak conviction. It is structural exhaustion of a defence built for a different world.
The Q2 outflows are not a verdict on loan quality. They are a verdict on a product structure that was sold as semi-liquid to clients who wanted fully liquid. The trade is in the platform stocks, not the BDC NAVs.
John Grey — Macro & cross-asset desk The Federal Reserve held its target range at 3.50 to 3.75 percent for the fourth consecutive meeting on Wednesday. The unanimous 12-0 vote was the headline. It was also the least important thing that happened in Washington this week. The
John Grey — Healthcare & longevity desk On the morning the markets were busy pricing a US-Iran ceasefire and a Federal Reserve hold, GSK’s new chief executive wrote the largest cheque of his tenure for a Cambridge, Massachusetts biotech that has yet to generate a single dollar of commercial